Cough - Pipeline Review, H2 2019

Published by Global Markets Direct on 18th November 2019 | Ref: 1464099 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Cough - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough - Pipeline Review, H2 2019, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or a sour taste in mouth. Risk factors include laryngopharyngeal reflux, allergies, reduced hydration, smoking, asthma, chronic bronchitis, gastroesophageal reflux and chemical sensitivities. Treatment for cough includes antihistamines, decongestants, antibiotics and cough suppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cough - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 10, 5, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cough - Overview

Cough - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cough - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cough - Companies Involved in Therapeutics Development

Alitair Pharmaceuticals Inc

Antheia Inc

Axalbion SA

Bayer AG

Beijing Tide Pharmaceutical Co Ltd

Charleston Laboratories Inc

Conrig Pharma ApS

Develco Pharma Schweiz AG

Evotec SE

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Merck & Co Inc

NeRRe Therapeutics Ltd

Nocion Therapeutics Inc

Orbis Biosciences Inc

PhytoHealth Corp

Roivant Sciences Ltd

Shionogi & Co Ltd

SolAeroMed Inc

Trevi Therapeutics Inc

Tris Pharma Inc

Cough - Drug Profiles

Ax-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AX-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1817080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1902607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzonatate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gefapixant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrocodone bitartrate + Undisclosed drug - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levodropropizine CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalbuphine hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORB-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orvepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHCA-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1226 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-600918 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 for Endometriosis and Chronic Cough - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 for Endometriosis and Chronic Cough - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chronic Cough - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Cough - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Sodium Channels for Cough - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDI-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRN-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRN-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRN-124 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cough - Dormant Projects

Cough - Discontinued Products

Cough - Product Development Milestones

Featured News & Press Releases

Oct 02, 2019: Congress presentation on clinical study of S-600918, a drug candidate for the treatment of Refractory/Unexplained Chronic Cough

Aug 26, 2019: BELLUS Health strengthens leadership team with appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer

Jul 31, 2019: Bellus Health starts recruitment in Phase II chronic cough trial

Jul 25, 2019: Evotec SE: P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC)

Jul 25, 2019: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough

Jul 15, 2019: BELLUS Health convenes KOL meeting to discuss the state of chronic cough treatment

Jun 07, 2019: NeRRe Therapeutics announces positive findings from phase 2b study with orvepitant in chronic cough

May 21, 2019: BELLUS Health presents Phase 1 data for BLU-5937, its lead product candidate for the treatment of refractory chronic cough, at the American Thoracic Society International Conference

May 15, 2019: BELLUS Health to present at three upcoming healthcare investor conferences

May 08, 2019: BELLUS Health provides update on its chronic cough drug candidate BLU-5937

Apr 04, 2019: BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences

Apr 03, 2019: BELLUS Health announces clearance of U.S. IND for BLU-5937 phase 2 study in chronic cough patients

Feb 28, 2019: Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer

Dec 12, 2018: Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate

Nov 14, 2018: BELLUS Health updates BLU-5937 top-line phase 1 results timeline to November 2018

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1464099 | GMDHC11450IDB

Number of Pages

99

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Data
30-06-2017

$2,500 USD

Published by Global Markets Direct
27-06-2017

$2,000 USD

Published by Global Markets Direct
31-03-2017

$2,000 USD

Published by Global Markets Direct
30-12-2016

$2,000 USD

Published by Global Data
17-10-2014

$995 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Cough - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.